Evec, bio-venture for development of antibody therapeutics

DOI Web Site 1 Citations 1 References
  • Takada Kenzo
    Evec, Inc., Founder and Chairman, Representative director

Bibliographic Information

Other Title
  • 抗体ベンチャー（イーベック）
  • コウタイ ベンチャー(イーベック)

Search this article

Abstract

Human blood B-lymphocytes are activated through natural immune reaction, such as reaction to infection. B-lymphocytes are stimulated repeatedly with a small amount of antigen, and thus only those producing high affinity antibodies are activated. Consequently the lymphocytes producing the antibodies with high-affinity are accumulated in human blood. Therefore, human lymphocytes are an excellent source of high-affinity antibodies. Evec, Inc. has established a unique method to develop high-affinity antibodies from human lymphocytes, using Epstein-Barr virus (EBV) which has the activity to induce proliferation of B-lymphocytes. The method is to induce proliferation of B-lymphocytes from human blood using EBV, and isolate those producing antibodies of interest. Here, I describe Exec's antibody technology and experiences of license negotiations with Mega Pharmas.

Journal

  • Drug Delivery System

    Drug Delivery System 27 (1), 40-46, 2012

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

Citations (1)*help

See more

References(1)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top